Sensitivity of Primary Clonogenic Blasts from Acute Lymphoblastic Leukemia Patients to an Activated Cyclophosphamide, viz., Mafosfamide

References

• Brock N. Oxazaphosphorine cytostatics: Past-present-future. Cancer Res. 1989; 49: 1
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Thiel E., Loffler H., Buchner T., Ganser A., Heil G., Koch F., Freund M., Diedrich H., Ruhl H., Maschmeyer G., Lipp T., Nowrousian M. R., Burkert M., Gerecke D., Pralle H., Muller U., Lunscken Ch., Fulle H., Ho A. D., Kuchler R., Busch F. W., Schneider W., Gorg C. H., Emmerich B., Braumann D., Vaupel H. A., von Paleske A., Battels H., Neiss A., Messerer D. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123
   PubMed Web of Science ®Google Scholar
• Crist W., Pullen J., Boyett J., Falletta J., van Eys J., Borowitz M., Jackson J., Dowell B., Frankel L., Quddus F., Ragab A., Viette T. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group study. Blood 1986; 67: 135
   PubMed Web of Science ®Google Scholar
• Rivera G. K., Buchanan G., Boyett J. M., et al. Intensive treatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group study. N. Engl. J. Med. 1986; 315: 273
   PubMed Web of Science ®Google Scholar
• Brochstein J. A., Kernan N. A., Groshen S., Cirrincione C., Shank B., Emanuel D., Laver J., O'Reilly R. J. Allogeneic bone marrow transplantation after hyper-fractionated total-body-irradiation and cyclophosphamide in children with acute leukemia. N. Engl. J. Med. 1987; 317: 1618
   PubMed Web of Science ®Google Scholar
• Dopfer R., Henze G., Gotze-Bender C., et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 1991; 78: 2780
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., Le Bien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., Hurd D., Ramsay N. K. C. Comparison of autologous and allogeneic BM transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461
   PubMed Web of Science ®Google Scholar
• Barrett J., Horowitz M. M., Gale R. P., Biggs J. C., Camitta B. M., Dicke K. A., Gluckman E., Good R. A., Herzig R. H., Lee M. B., Marmont A. M., Masaoka T., Ramsay N. K. C., Rimm A. A., Speck B., Zwaan F. E., Bortin M. M. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989; 74: 862
   PubMed Web of Science ®Google Scholar
• Kaizer H., Stuart R. K., Brookemeyer R., Beschorner W. E., Braine H. G., Burns W. H., Fuller D. J., Korbling M., Mangan K. F., Saral R., Sensengbrenner L., Shad-Duck R K, Shende A. D., Tutschka P. J., Yeager A. M., Zinkham W. H., Colvin O. M., Santos G. W. Autologous BM transplantation in acute leukemia. Blood 1985; 65: 1504
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., Ledbetter J. A., Weisdorf D., Myers D. E., Haake R., Ramsay N. K. C. Autologous BM transplantation in high risk remission T-lineage acute lymphoblastic leukemia using im-munotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Haake R., Weisdorf D., Ledbetter J. A., Ramsay N. K. C. Autologous BM transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo BM purging. Blood 1992; 79: 1094
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Haissig S., Ledbetter J. A., Fidler P., Wad-Dick K, Hanson M., Kuebelbeck V., Weisdorf D., Gajl-Peczalska K., Myers D. E., Kersey J. H., Ramsay N. K. C. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation (BMT) using autografts depleted of CD19+ B-cell precursors by an anti-CD19 Pan-B cell immunotoxin containing poke-weed antiviral protein. Blood 1992; 79: 3369
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ramsay N. K. C., Nesbit M., Kersey J. H., Song C. W. Immunophenotype predicts radiation resistance in T-lineage acute lymphoblastic leukemia and T-lineage non-Hodgkin's lymphoma. Int. J. Radial. Oncol. Biol. Phys. 1992; 24: 705
   Web of Science ®Google Scholar
• Sladek N. Metabolism of oxazaphosphorines. Pharmacol. Therap. 1988; 37: 301
   PubMed Web of Science ®Google Scholar
• Sladek N. E. Oxazaphosphorine-specific acquired resistance. Mechanisms of Drug Resistance in Oncology, B. A. Teicher. Marcel Dekker, New York 1993, 1993, in press.
   Google Scholar
• Dockham P. A., Lee M. O., Sladek N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol. 1992; 43: 2453
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajl-Peczalska K. J., Kersey J. H., Houston L. L., Vallera D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med. 1986; 163: 347
   PubMed Web of Science ®Google Scholar
• Sladek N. E., Low J. E., Landkamer G. J. Collateral sensitivity to cross-linking agents exhibited by cultured LI210 cells resistant to oxazaphosphorines. Cancer Res. 1985; 45: 625
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Myers D. E., Jaszcsz W., Haissig S., Gajl-Peczalska K., Ledbetter J. A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood, 76: 2449
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajl-Peczalska K. J., Ledbetter J. A., Roller B. Biphenotypic leukemic lymphocyte precursors in CD2′ CD19f acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989; 73: 1000
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ramakrishnan S., Houston L. L. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell specific immunotoxin containing poke-weed antiviral protein. Cancer Res. 1985; 45: 69
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Stong R. C., Youle R., Vallera D. A. Combined ex vivo treatment with immunotoxins and mafosfamide: A novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. J. Immunol. 1985; 134: 3504
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Fauci A. S., Song C. W., Mehta S. R., Heerema N. A., Gajl-Peczalska K. J., Ambrus J. L. B-cell growth factor receptor expression and B cell growth factor response of leukemic B-cell precursors and B-lineage lymphoid progenitor cells. Blood 1987; 70: 1020
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Myers D. E., Ledbetter J. A., Swaim S. E., Gajl-Peczalska K. J., Vallera D. A. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. J. Immunol. 1988; 140: 2103
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ledbetter J. A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc. Natl. Acad. Sci. USA 1988; 85: 8603
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Heerema N. A. Use of lymphoid progenitor cell assays for a more detailed analysis of the cytogenetic changes occurring during clonal evolution in acute lymphoblastic leukemia. Leukemia and Lymphoma 1990; 2: 1
   PubMedGoogle Scholar
• Manthey C. L., Landkamer G. J., Sladek N. E. Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. Cancer Res. 1990; 50: 4991
   PubMed Web of Science ®Google Scholar
• Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit. Rev. Biochem. Mol. Biol. 1992; 27: 283
   PubMed Web of Science ®Google Scholar
• Habig W. H., Jakoby W. B. Assays for differentiation of glutathione S-transferases. Meth. Enzymol. 1981; 77: 398
   PubMedGoogle Scholar
• Hantel A., Hilton J., Russo J. E., Donehower R. C., Colvin O. M. Glutathione content, glutathione S-transferase profiles and melphalan sensitivity in murine hematopoietic cell lines. Proc. Am. Assoc. Cancer Res. 1988; 29: 297
   Web of Science ®Google Scholar
• Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Application to mammalian blood and other tissues. Anal. Biochem. 1969; 27: 502
   PubMed Web of Science ®Google Scholar
• Albright N. Computer programs for the analysis of cellular survival data. Radiat. Res. 1987; 112: 331
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ramsay N. K. C., Waddick K. G., Jaszcz W., Chandan-Langlie M., Obuz V., Haake R., Gajl-Peczalska K., Kersey J. H., Song C. W. In vitro and in vivo radiation resistance associated with CD3 surface antigen expression in T-lineage acute lymphoblastic leukemia. Blood 1991; 78: 2945
   PubMed Web of Science ®Google Scholar
• Sladek N. E., Doeden D., Powers J. F., Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phospharamide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep. 1984; 68: 1247
   PubMedGoogle Scholar
• Sladek N. E., Landekamer G. J. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res. 1985; 45: 1549
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajl-Peczalska K. J., Myers D. E., Ramsay N. K. C., Kersey J. H., Colvin M., Vallera D. A. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: Efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclo-phosphamide against fresh leukemic marrow progenitor cells. Blood 1987; 69: 361
   PubMed Web of Science ®Google Scholar
• Kohn F. R., Landkamer G. J., Manthey C. L., Ramsay N. K. C., Sladek N. E. Effect of aldehyde de-hydrongenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Cancer Res., Ail 1987; 3180
   Google Scholar
• Makrynikola V., Kabral A., Bradstock K. F. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 8: 351
   PubMed Web of Science ®Google Scholar
• Miller C. B., Zehnbauer B. A., Piantadosi S., Rowley S. D., Jones R. J. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78: 1125
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans H. C., Martens A. C. M., Lowenberg B., Hagenbeek A. No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. Leukemia Res. 1984; 8: 723
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Douay L., Laporte J. P., Lopez M., Mary J. Y., Najman M. A., Salmon C., Aegerter P., Shach-Owiak J., David R., Pene F., Kantor G., Deloux J., Du-Hamel E, van den Akker J., Gerota J., Parlier Y., Duhamel G. Autologous bone marrow transplantation using marrow incubated with ASTA Z 7557 in adult acute leukemia. Blood 1986; 67: 1367
   PubMed Web of Science ®Google Scholar
• Mortensen B. T., Ernst P., Philip P. Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukemia. Eur. J. Haematol. 1988; 41: 218
   PubMed Web of Science ®Google Scholar
• Jones R. J., Miller C. B., Zehnbauer B. A., Rowley S. D., Colvin O. M., Sensenbrenner L. L. In vitro evaluation of combination drug purging for autologous bone marrow transplantation. Bone Marrow Transplant 1990; 5: 301
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Mangoni L., Almici C., Garau D., Cra-Viotto L, Piovani G., Caramatti C., Rizzoli V. Differential sensitivity of adherent CFU-blast, CFU-Mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. Exp. Hematol. 1992; 20: 328
   PubMed Web of Science ®Google Scholar
• Gordon M. Y., Goldman J. M., Gordon-Smith E. C. 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leukemia Res. 1985; 9: 1017
   PubMed Web of Science ®Google Scholar
• Daniels J. R., Daniels A. M., Luck E. E., Whitman B., Casagrande J. T., Skinner D. G. Chemosensitiv-ity of human neoplasms with in vitro clone formation. Cancer Chemother. Pharmacol. 1981; 6: 245
   PubMedGoogle Scholar
• Lerman S. P., Weidanz W. P. Effect of cyclophosphamide on ontogeny of humoral immune response in chickens. J. Immunol. 1970; 105: 614
   PubMed Web of Science ®Google Scholar
• Turk J. L., Poulter L. W. Selective depletion of lymphoid tissue by cyclophosphamide. Clin. Exp. Immunol. 1972; 10: 285
   PubMed Web of Science ®Google Scholar
• Turk J. L., Parker D., Poulter L. W. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 1972; 23: 493
   PubMed Web of Science ®Google Scholar
• Stockman G. D., Heim L. R., South M. A., Trentin J. J. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J. Immunol. 1973; 110: 277
   PubMed Web of Science ®Google Scholar
• Ghaffar A., Sigel M. M., Huggins E. M. Differential effects of cyclophosphamide on lymphocyte sub-populations. Fed. Proc 1983; 42: 945
   Google Scholar
• Smith P. C., Sladek N. E. Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxaza-phosphorine nitrogen mustards. Biochem. Pharmacol. 1985; 34: 3459
   PubMed Web of Science ®Google Scholar
• Misra R. R., Bloom S. E. Roles of dosage, pharmacokinetics, and cellular sensitivity to damage in the selective toxicity of cyclophosphamide towards B and T cells in development. Toxicology 1991; 66: 239
   PubMed Web of Science ®Google Scholar
• Wilmer J. L., Colvin O. M., Bloom S. E. Cytogenetic mechanisms in the selective toxicity of cyclophosphamide analogs and metabolites towards avian embryonic B lymphocytes in vivo. Mutation Res. 1992; 268: 115
   PubMed Web of Science ®Google Scholar
• Wilmer J. L., Bloom S. E. A cytogenetic approach for detecting the selective toxicity of drugs in avian embryonic B and T lymphocytes. Mutation Res. 1991; 253: 161
   PubMed Web of Science ®Google Scholar
• Kwanyuen P., Erexson G. L., Bryant M. F., Kliger-Man A. D. Comparison of sister-chromatid exchange frequencies in mouse T- and B-lymphocytes after exposure to 4-hydroxycyclophosphamide or phosphoramide mustard. Mutation Res. 1990; 245: 293
   PubMed Web of Science ®Google Scholar
• Misra R. R., Lorr N. A., Bloom S. E. Cyclophosphamide metabolism in the primary immune organs of the chick: assays of drug activation, P450 expression, and aldehyde dehydrogenase. Arch. Toxicol. 1991; 65: 32
   PubMed Web of Science ®Google Scholar
• Kastan M. B., Schlaffer E., Russo J. E., Colvin O. M., Civin C. I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 1947
   PubMed Web of Science ®Google Scholar
• Smith P. C. The effect of oxazaphosphorine and non-oxazaphosphorine DNA crosslinking agents on murine lymphoid cells. University of Minnesota, Minneapolis, Minnesota 1989, Ph.D. Thesis
   Google Scholar
• Roederer M., Staal F. J. T., Osada H., Herzenberg L. A., Herzenberg L. A. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol. 1991; 3: 933
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Chelstrom L. M., Finnegan D., Tuel-Ahl-Gren L, Manivel C., Irvin J. D., Myers D. E., Gunther R. Effective immunochemotherapy of CALLA+Cji+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116
   PubMed Web of Science ®Google Scholar